Next Quarterly Earnings
Date confirmed from the company's own financial calendar.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Genmab is an international Danish biotechnology company focused on the research, development, and commercialization of innovative antibody therapeutics. The company is dedicated to improving the quality of life for patients with cancer and other serious diseases by bringing groundbreaking medicines to market.
Date confirmed from the company's own financial calendar.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Genmab is scheduled to report its next quarterly earnings on 11/05/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Genmab last reported quarterly earnings on 8/6/2026 (Q2 2026). Earnings per share (EPS) came in at 32.21 DKK.
Across its last 4 earnings reports, Genmab stock moved by ±1.7% on average the following day. The largest reaction was +4.4% on 02/17/2026; 3 of 4 reactions were positive.
Genmab has beaten analyst EPS estimates in 3 of its last 5 evaluated quarters (beat rate: 60%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 4 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.